AEterna Zentaris Inc. (NASDAQ:AEZS) Set to Announce Earnings on Thursday
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, August 10th. Analysts expect AEterna Zentaris to post earnings of ($0.41) per share for the quarter.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.85 million. AEterna Zentaris had a negative return on equity of 425.52% and a negative net margin of 2,732.69%. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.37) earnings per share. On average, analysts expect AEterna Zentaris to post $-1.56 EPS for the current fiscal year and $-0.8 EPS for the next fiscal year.
AEterna Zentaris Inc. (NASDAQ AEZS) opened at 1.90 on Tuesday. The stock’s market cap is $27.23 million. The stock’s 50 day moving average price is $1.36 and its 200-day moving average price is $2.12. AEterna Zentaris Inc. has a 12 month low of $0.78 and a 12 month high of $5.59.
Several research firms recently weighed in on AEZS. Maxim Group set a $2.00 price target on shares of AEterna Zentaris and gave the stock a “buy” rating in a research report on Saturday, July 1st. Zacks Investment Research upgraded shares of AEterna Zentaris from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, HC Wainwright reduced their price target on shares of AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating for the company in a research report on Wednesday, May 10th.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.